The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Subscribe To Our Newsletter & Stay Updated
